Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $18.33.

KYTX has been the topic of several recent analyst reports. HC Wainwright cut their target price on Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, April 3rd. Morgan Stanley lowered their price target on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, April 1st.

Kyverna Therapeutics Price Performance

Shares of Kyverna Therapeutics stock opened at $1.91 on Tuesday. Kyverna Therapeutics has a 1 year low of $1.79 and a 1 year high of $24.91. The firm’s 50-day moving average is $2.67 and its 200 day moving average is $3.91. The stock has a market cap of $82.54 million, a price-to-earnings ratio of -0.55 and a beta of 2.57.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.01). On average, equities analysts expect that Kyverna Therapeutics will post -3.29 EPS for the current fiscal year.

Institutional Trading of Kyverna Therapeutics

Large investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Kyverna Therapeutics by 16.7% in the fourth quarter. Wellington Management Group LLP now owns 274,414 shares of the company’s stock valued at $1,026,000 after acquiring an additional 39,291 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of Kyverna Therapeutics in the fourth quarter worth approximately $125,000. Squarepoint Ops LLC bought a new stake in Kyverna Therapeutics during the fourth quarter valued at approximately $43,000. Two Sigma Advisers LP increased its holdings in Kyverna Therapeutics by 375.1% during the fourth quarter. Two Sigma Advisers LP now owns 80,290 shares of the company’s stock valued at $300,000 after buying an additional 63,390 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in Kyverna Therapeutics by 47.9% in the fourth quarter. Two Sigma Investments LP now owns 181,654 shares of the company’s stock worth $679,000 after acquiring an additional 58,800 shares during the period. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.